Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

webinar

Thu, 27 Oct 2022, 16:00 CEST (Berlin)

Dr. Xavier Morelli, Centre de Recherche en Cancérologie de Marseille (CRCM), France

Integrated Strategy for Hit-to-Lead Optimization: The ‘DOTS’ approach

In recent decades, the identification of hits has been greatly facilitated by advances in high throughput screening (HTS) and the design of chemical libraries. It would be wishful to optimize the automation of the ‘hit-to-lead’ (H2L) process. Xavier will present an integrated strategy for the H2L optimization phase and the automated design of chemical probes called Diversity Oriented Target-Focused Synthesis (DOTS and CovaDOTS) approach.
In the ‘DOTS’ approach, a focused virtual library is generated by combining an activated fragment — corresponding to a substructure that binds to a target — with a collection of functionalized chemical blocks, using in silico encoded relevant chemical reactions. Target-specific compounds are selected by virtual screening, followed by in vitro synthesis and evaluation using a robotic platform. The proof of concept was successfully completed by the optimization of bromodomain inhibitors that lead to the validation of several compounds with an affinity that had improved by several orders of magnitude. The proposed process can be implemented in academic environments or biotechnology companies that desire an automation of these processes.

 

Register and tune in for a very exciting webinar.

1 Hoffer L. et al. J. Med. Chem. 2018 Jul 12;61(13):5719-5732; Carrasco K. et al., J. Med. Chem. 2022 Apr 14;65(7):5660-5674 

2 Hoffer L., et al. J. Chem. Inf. Model. 2019 2019 Apr 22;59(4):1472-1485

Current news

category
Events
Recordings of the BioSolveIT Day 2025 Available
October 15, 2025 13:39 CEST
Missed BioSolveIT Day 2025? The recordings from BioSolveIT Day 2025 are now live! Packed with practical insights for medicinal and computational chemists, the sessions showcase how SeeSAR, infiniSee, Chemical Space Docking®, and CoLibri accelerate real-world discovery, from pocket-aware design and HYDE-guided decisions to trillion-scale, synthesizable chemical space exploration and in-house...
Read on
Enamine’s REAL Space September 2025 Update - Now 83 Billion!
September 23, 2025 10:31 CEST
The September 2025 update of Enamine’s REAL Space brings a new expansion, now featuring over 83 billion accessible, drug-like products, up from 76 billion in the previous release. Built from 172 curated reactions and 192,487 reagents and building blocks based on in-house knowledge, this version further enhances one of the...
Read on
WuXi’s GalaXi Space September 2025 – Expanded to 26 Billion Molecules!
September 17, 2025 10:03 CEST
The September 2025 update of WuXi LabNetwork’s GalaXi Space delivers a major expansion, now featuring over 25.8 billion synthesis-ready products. Built from 185 curated reactions and 30,877 high-quality building blocks, GalaXi is one of the largest tangible Chemical Spaces for modern drug discovery. This release broadens structural diversity with novel...
Read on